Cumberland Pharmaceuticals Net Income Over Time
| CPIX Stock | USD 3.86 0.11 2.93% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cumberland Pharmaceuticals Performance and Cumberland Pharmaceuticals Correlation. Cumberland | Build AI portfolio with Cumberland Stock |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cumberland Pharmaceuticals. Projected growth potential of Cumberland fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cumberland Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.24) | Revenue Per Share | Quarterly Revenue Growth (0.09) | Return On Assets | Return On Equity |
Cumberland Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Cumberland's balance sheet. Smart investors calculate Cumberland Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Cumberland Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cumberland Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cumberland Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cumberland Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Cumberland Pharmaceuticals and related stocks such as Quantum BioPharma, Rockwell Medical, and ABVC Biopharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QNTM | (32.8 K) | (32.8 K) | (32.8 K) | (32.8 K) | (32.8 K) | (32.8 K) | (29.6 K) | (2.8 M) | (16.7 M) | (39.1 M) | (31.8 M) | (35.3 M) | (23.6 M) | (17.9 M) | (14.2 M) | (12.8 M) | (13.4 M) |
| RMTI | (1.9 M) | (21.4 M) | (54 M) | (48.8 M) | (21.3 M) | (14.4 M) | (19.8 M) | (25.9 M) | (32.1 M) | (34.1 M) | (30.9 M) | (32.7 M) | (18.7 M) | (8.4 M) | (480 K) | (432 K) | (453.6 K) |
| ABVC | (20 K) | (1.2 M) | (24.1 K) | (24.1 K) | (24.1 K) | (32.3 K) | (11 M) | (4.2 M) | (5.6 M) | (3.6 M) | (9.8 M) | (12.8 M) | (16.4 M) | (7.8 M) | (4.9 M) | (4.4 M) | (4.6 M) |
| LTRN | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (2.4 M) | (5.9 M) | (12.4 M) | (14.3 M) | (16 M) | (20.8 M) | (18.7 M) | (17.8 M) |
| NOTV | 700 K | (6.4 M) | 773 K | (1.1 M) | 1.1 M | (3.2 M) | 884 K | (194 K) | (790 K) | (4.7 M) | 10.9 M | (337.3 M) | (105.1 M) | (108.4 M) | (68.6 M) | (61.8 M) | (58.7 M) |
| CALC | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (37 M) | (27.5 M) | (35.8 M) | (7.8 M) | (34.4 M) | (13.7 M) | (15.8 M) | (16.5 M) |
| DYAI | (190.8 K) | 1.3 M | 1.3 M | (428.1 K) | (6 M) | 65.8 M | (3.6 M) | (2.1 M) | (5.7 M) | (8.3 M) | (9.3 M) | (13.1 M) | (9.7 M) | (6.8 M) | (5.8 M) | (5.2 M) | (5 M) |
| RVPH | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (846.8 K) | (3.8 M) | (8.5 M) | (24.3 M) | (39.3 M) | (29.9 M) | (26.9 M) | (25.6 M) |
| CELU | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (211.9 M) | (208.2 M) | (100.1 M) | 14.2 M | (196.3 M) | (57.9 M) | (66.6 M) | (69.9 M) |
Cumberland Pharmaceuticals and related stocks such as Quantum BioPharma, Rockwell Medical, and ABVC Biopharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Cumberland Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Cumberland Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Cumberland Pharmaceuticals | CPIX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1600 West End |
| Exchange | NASDAQ Exchange |
USD 3.86
Additional Tools for Cumberland Stock Analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.